ID: ALA4100617

Max Phase: Preclinical

Molecular Formula: C22H22N4O5

Molecular Weight: 422.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cnc2c(c1)C(=O)c1c-2n(CCCNC(C)C)c(=O)c2cc([N+](=O)[O-])ccc12

Standard InChI:  InChI=1S/C22H22N4O5/c1-12(2)23-7-4-8-25-20-18(21(27)17-10-14(31-3)11-24-19(17)20)15-6-5-13(26(29)30)9-16(15)22(25)28/h5-6,9-12,23H,4,7-8H2,1-3H3

Standard InChI Key:  XOJIAQZVODHKEX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 422.44

Molecular Weight (Monoisotopic): 422.1590

AlogP: 2.91

#Rotatable Bonds: 7

Polar Surface Area: 116.36

Molecular Species: BASE

HBA: 8

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 10.33

CX LogP: 1.54

CX LogD: -1.22

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.28

Np Likeness Score: -0.56

References

1. Wang P, Elsayed MSA, Plescia CB, Ravji A, Redon CE, Kiselev E, Marchand C, Zeleznik O, Agama K, Pommier Y, Cushman M..  (2017)  Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).,  60  (8): [PMID:28418653] [10.1021/acs.jmedchem.6b01565]

Source

Source(1):

• Scientific Literature